Themis Medicare Faces Operational Challenges Amid Flat Q2 FY24-25 Performance

Themis Medicare, a small-cap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation adjustment that reflects its current market standing. The company has reported flat financial performance for the quarter ending Q2 FY24-25, with key metrics indicating challenges in its operational efficiency.
The company's Debt to EBITDA ratio stands at 1.01 times, suggesting a constrained ability to manage its debt obligations. Additionally, the Net Sales growth rate over the past five years has been modest at 17.78% annually, raising concerns about its long-term growth prospects. The cash and cash equivalents have reached a low of Rs 17.60 crore, while the Debtors Turnover Ratio is at 2.09 times, indicating potential liquidity issues.

Despite a return of -6.85% over the past year, Themis Medicare's profits have seen a slight increase of 3.4%. The company's Return on Capital Employed (ROCE) is recorded at 11.1, and its valuation appears expensive with an Enterprise Value to Capital Employed ratio of 4.5. Notably, domestic mutual funds hold no stake in the company, which may reflect a cautious sentiment regarding its valuation and business outlook.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.